Xenetic Biosciences, Inc. (XBIO)

Expanding the Potential of CAR T Cell Therapy

Xenetic Biosciences is a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.

More About Us

Combating Disease Through Innovative Therapies

Product Pipeline

Platform

Personalized CAR T platform targeting cancers with a patient- and tumor-specific approach.

XCART Platform

Transformative Technologies

Our proprietary and patented technologies are being utilized to create life-changing therapies.

Our Novel Technologies

Latest News

May 18, 2022

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

May 12, 2022

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Stock Information • View Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.

Price

Change

Volume

Day Range

52 Week Range

Investor Presentation

View Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates